P. R. Lowenstein

Epigenetic reprogramming of autophagy leads to uncovering a novel therapeutic target for mutant IDH1 astrocytomas

This study identifies autophagy as a critical survival pathway in mIDH1 gliomas and shows that inhibiting autophagy enhances radiosensitivity and tumor regression in preclinical models.

Modeling Glioma Oncostreams In Vitro: Spatiotemporal Dynamics of their Formation, Stability, and Disassembly

This paper models glioma oncostreams in vitro, showing their formation, stability, and response to pharmacological agents, with insights into potential anti-invasion targets.

De novo lipogenesis pathway is a vulnerability in IDH1 mutant glioma

This study identifies de novo lipogenesis as a vulnerability in IDH1 mutant gliomas, showing that HDAC inhibition and FASN targeting reduce tumor growth and improve survival.

Zinc Finger MYND-Type Containing 8 (ZMYND8) is epigenetically regulated in mutant Isocitrate Dehydrogenase 1 (IDH1) glioma to promote radioresistance

This paper identifies ZMYND8 as a gene epigenetically regulated by mIDH1 that promotes radioresistance in glioma cells, and shows its knockdown enhances radiosensitivity.

Systemic delivery of a CXCR4-CXCL12 signaling inhibitor encapsulated in synthetic protein nanoparticles for glioma immunotherapy

This paper develops synthetic protein nanoparticles delivering a CXCR4 inhibitor to treat glioma by enhancing immunotherapy and reducing tumor progression.

Radiation-reprogrammed glioma stem cells generate vascular-like cells to build a trophic niche driving tumor recurrence

The paper shows radiation induces vascular-like phenotypes in glioma stem cells, creating a trophic niche that promotes tumor recurrence, and identifies P300 inhibition as a potential therapeutic strategy.

Spatiotemporal analysis of glioma heterogeneity reveals Col1A1 as an actionable 1 target to disrupt tumor mesenchymal differentiation, invasion and malignancy

The paper identifies COL1A1 as a key driver of glioma mesenchymal differentiation and invasion, showing its inhibition disrupts tumor structure and improves survival.

Inhibition of 2-Hydroxyglutrate Elicits Metabolic-reprograming and Mutant IDH1 Glioma Immunity

This study shows that inhibiting 2-hydroxyglutarate in mIDH1 gliomas with ATRX/TP53 inactivation improves survival and induces anti-tumor immunity through immunological memory and reduced T-cell exhaustion.

Systemic Brain Tumor Delivery of Synthetic Protein Nanoparticles for Glioblastoma Therapy

This study develops synthetic protein nanoparticles for GBM therapy, showing they deliver STAT3i siRNA to tumors, enhance radiation response, and induce immune memory in mice.

FYN tyrosine kinase, a downstream target of receptor tyrosine kinases, modulates anti-glioma immune responses

This study shows that FYN tyrosine kinase in glioma cells suppresses anti-glioma immune responses, and its inhibition reduces tumor growth and improves survival in immune-competent models.